How would you approach a metastatic ERBB2 amplified gallbladder carcinoma?
Would you consider adding trastuzumab to cis/gem in the first line? If not, would you consider adding Her2 directed therapy to FOLFIRI or FOLFOX in the second line? Or would you go to Pertuzumab/trastuzumab combination given MyPathway data. This in the setting of a patient who is not a trial candidate.
Answer from: Medical Oncologist at Community Practice
You have hit on a clinical scenario for which we have clues about helpful therapy, but no definitive data to guide us.
For a HER-2 amplified gallbladder or biliary cancer, I do think the data support targeting this pathway at some point in the patient’s care. As you point out, the best ...
Sign in or Register to read more